Joanna Jonska-Gmyrek1,2, Agnieszka Zolciak-Siwinska3, Leszek Gmyrek4, Wojciech Michalski2, Grazyna Poniatowska2, Malgorzata Fuksiewicz5, Pawel Wiechno2, Jakub Kucharz2, Maria Kowalska5, Beata Kotowicz5. 1. Department of Radiotherapy, Maria Sklodowska, Curie Institute, Oncology Center, Warsaw, Poland. 2. Department of Urooncology, Maria Sklodowska, Curie Institute, Oncology Center, Warsaw, Poland. 3. Department of Brachytherapy, Maria Sklodowska, Curie Institute, Oncology Center, Warsaw, Poland. 4. The Holy Family Hospital, Warsaw, Poland. 5. Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska, Curie Institute, Oncology Center, Warsaw, Poland.
Abstract
BACKGROUND/AIMS: Serous carcinoma of the uterine cervix (USCC) is an extremely rare subtype. To establish the treatment strategy in patients with USCC is an important issue. METHODS: MEDLINE (PubMed) was searched for all articles published after the first publication by Lurie et al. [Eur J Obstet Gynecol Reprod Biol 1991; 40: 79-81], reporting woman diagnosed with USCC. Because of limited numbers of studies on the topic of the study, we could not keep a restriction of eliminating smaller sample sizes. RESULTS: A search of PubMed demonstrated that 113 cases of USCC have been reported in the literature since the first publication. The current treatment modality adopted for early cervical cancer is hysterectomy with bilateral iliac-obturator lymphadenectomy and postoperative radiotherapy (RT) or radiochemotherapy (RT-CT) if risk factors for cervical carcinoma appear. The treatment strategy for locally advanced USCC is preoperative RT-CT or chemotherapy (CHTH) with the intention to treat the patient surgically. The treatment option for disseminated disease is CHTH with paclitaxel and carboplatin. CONCLUSION: Risk factors and a more advanced clinical stage of USCC have an impact on poor outcomes despite the use of standard treatment methods, adapted for cervical cancer. The outside-pelvic failures tend to seek effective systemic treatment.
BACKGROUND/AIMS: Serous carcinoma of the uterine cervix (USCC) is an extremely rare subtype. To establish the treatment strategy in patients with USCC is an important issue. METHODS: MEDLINE (PubMed) was searched for all articles published after the first publication by Lurie et al. [Eur J Obstet Gynecol Reprod Biol 1991; 40: 79-81], reporting woman diagnosed with USCC. Because of limited numbers of studies on the topic of the study, we could not keep a restriction of eliminating smaller sample sizes. RESULTS: A search of PubMed demonstrated that 113 cases of USCC have been reported in the literature since the first publication. The current treatment modality adopted for early cervical cancer is hysterectomy with bilateral iliac-obturator lymphadenectomy and postoperative radiotherapy (RT) or radiochemotherapy (RT-CT) if risk factors for cervical carcinoma appear. The treatment strategy for locally advanced USCC is preoperative RT-CT or chemotherapy (CHTH) with the intention to treat the patient surgically. The treatment option for disseminated disease is CHTH with paclitaxel and carboplatin. CONCLUSION: Risk factors and a more advanced clinical stage of USCC have an impact on poor outcomes despite the use of standard treatment methods, adapted for cervical cancer. The outside-pelvic failures tend to seek effective systemic treatment.
Authors: Sul Lee; Hyun Joo Lee; Kyung Un Choi; Byung Su Kwon; Dong Soo Suh; Dae Hoon Jeong; Geun Joo Kim; Tae Hwa Lee; Hyun-Jin Roh; Ki Hyung Kim Journal: J Res Med Sci Date: 2020-05-22 Impact factor: 1.852